Notice of Nexstim Plc's Half-Yearly Report H1 2015

Helsinki, FINLAND

Helsinki, 30 July 2015 at 8.00 am

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, will publish its half half-yearly report for the six months ended 30 June 2015 on Thursday 20 August 2015 at approximately 8.00 am Finnish time.

A conference call for media, investors and analysts will take place at 3.00 pm Finnish time on Thursday 20 August 2015. Janne Huhtala, Chief Executive Officer, and Mikko Karvinen, Chief Financial Officer, will present the financial and operational results followed by a Q&A session. The presentation material will be available on the Nexstim website shortly before the conference call begins.

The dial-in numbers for the conference call are:

Finland:             +358 (0)9 231 95386

Sweden:           +46 (0)8 566 19407

UK:                      +44 (0)1452 557 851

US:                      +1 86 66 65 40 42

The call ID number is: 89136232


Janne Huhtala, CEO

For further information please visit or contact:

Nexstim                                                     +358 (0)40 8615046

Janne Huhtala, Chief Executive Officer

UB Capital Oy (Certified Adviser)                       +358 (0)9 2538 0225

Consilium Strategic Communications             +44 (0)20 3709 5700

Mary-Jane Elliott / Ivar Milligan

About Nexstim Plc

Nexstim, formed in 2000 and based in Finland, is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit


Notice of Nexstim Plc's Half-Yearly Report H1 2015